GlassScriptPhysician profile
Stephen L Nichols
NPI 1568459469
$1,343.09
in general payments reported to CMS, 2019-2025
23 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $102 · 2021: $177 · 2022: $191 · 2023: $229 · 2024: $225 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.38 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $218.72 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $147.15 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Coopervision INC. | $126.09 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.04 | 2019-2021 | |
| Horizon Therapeutics Plc | $88.09 | 2020-2023 | Tepezza |
| Biotissue Holdings INC. | $83.94 | 2019-2024 | |
| Alcon Vision LLC | $79.01 | 2020-2025 | Rocklatan, Tryptyr, Clareon |
| Dompe US, INC. | $66.69 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $60.25 | 2019-2022 | |
| Oyster Point Pharma, INC. | $54.91 | 2023-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $50.40 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $42.17 | 2019-2025 | Lipiflow System Activator (Disposable), Lipiflow System Activator II (Disposable |
| Allergan, INC. | $32.14 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $30.62 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.48 | 2024 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.71 | 2023 | Iyuzeh |
| Lumenis, INC | $21.58 | 2021 | |
| Abb Con-Cise Optical Group LLC | $20.64 | 2025 | Contact Lens, Spectacle Lenses |
| Rxsight INC | $16.67 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Kerecis Limited | $15.90 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Synergeyes, INC. | $15.00 | 2022 | |
| Alcon Research LLC | $12.11 | 2019 | |
| Sight Sciences, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.